<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369703</url>
  </required_header>
  <id_info>
    <org_study_id>19-010785</org_study_id>
    <nct_id>NCT04369703</nct_id>
  </id_info>
  <brief_title>Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery</brief_title>
  <official_title>Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Access the optimal cut point value of copeptin which predicts development of central
           diabetes insipidus postoperatively with highest accuracy.

        2. Access the optimal cut point value of copeptin which predicts the lack of central
           diabetes insipidus postoperatively with highest accuracy

        3. Access the relative change in copeptin values between baseline and post-surgery as a
           predictor for diabetes insipidus development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient serum levels of copeptin would be measured after phlebotomy of 3 ml of blood in EDTA
      tube twice a) within 1-4 hours of extubation and b) within 4-24 hours of extubation (the
      morning following surgery).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2020</start_date>
  <completion_date type="Anticipated">January 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Predict central diabetes insipidus development</measure>
    <time_frame>2 years</time_frame>
    <description>Using the measured lab value, we will access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Predict lack of central diabetes insipidus development</measure>
    <time_frame>2 years</time_frame>
    <description>Using the measured lab value, we will access the optimal cut point value of copeptin which predicts the lack of central diabetes insipidus postoperatively with highest accuracy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess relative change</measure>
    <time_frame>2 years</time_frame>
    <description>Using the measured lab value, we will access the relative change in copeptin values between baseline and post-surgery as a predictor for diabetes insipidus development.</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Sellar and Suprasellar Masses</condition>
  <condition>Pituitary Tumor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with sellar and suprasellar masses.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        * Patients with sellar and suprasellar masses who undergo neurosurgical procedure at Mayo
        Clinic Rochester.

        Exclusion Criteria:

        * Patients with preexisting CDI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dana Erickson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew D Hoplin, MS</last_name>
    <phone>507-422-2121</phone>
    <email>Hoplin.Matthew@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandy Twaites</last_name>
    <phone>507-284-5775</phone>
    <email>Twaites.sandra@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew D Hoplin, MS</last_name>
      <phone>507-422-2121</phone>
      <email>Hoplin.Matthew@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sandy Twaites</last_name>
      <phone>507-284-5775</phone>
      <email>Twaites.Sandra@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dana Erickson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Dana Erickson</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Diabetes Insipidus</mesh_term>
    <mesh_term>Diabetes Insipidus, Neurogenic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

